POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders including type 2 diabetes and non-alcoholic steatohepatitis (NASH), has revealed new preclinical results for PXL770, the lead molecule in the company's adenosine monophosphate-activated protein kinase (AMPK) platform, it was reported on Monday'.
The platforms is a direct AMPK activator that was assessed in a rodent NASH model in combination with other key agents in development, including an FXR agonist (obeticholic acid), a GLP-1 receptor agonist (semaglutide) and a thyroid receptor β agonist (MGL-3196). The results revealed the product as a potentially novel NASH therapy that is also likely to produce complementary benefits when integrated with other agents with different mechanisms of action. The product was also assessed in rodent models of diabetic kidney disease that also evaluated cardiac dysfunction and adrenoleukodystrophy/ adrenomyeloneuropathy. These results indicate that AMPK activation is likely to lead to broader utility for other diseases mediated by metabolic pathway dysfunction.
David E Moller, MD, Poxel CSO, said, 'AMPK is a compelling pharmaceutical target that has been observed to modulate both metabolic and inflammatory pathways and has the potential to treat several chronic and rare metabolic diseases. Our new preclinical data highlights the potential of PXL770 to show even greater additive or synergistic benefits to treat the root causes of NASH when combined with other agents in development. We are also very excited by the new findings implicating the potential of PXL770 and, more broadly, of AMPK activation for the treatment of other serious chronic disorders ranging from common to rare monogenic metabolic disorders.'
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults